Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in a ferret model
- Guarnaccia, Teagan, Carolan, Louise, Maurer-Stroh, Sebastian, Lee, Raphael, Job, Emma, Reading, Patrick, Petrie, Stephen, McCaw, James, McVernon, Jodie, Hurt, Aeron, Kelso, Anne, Mosse, Jennifer, Barr, Ian, Laurie, Karen
- Authors: Guarnaccia, Teagan , Carolan, Louise , Maurer-Stroh, Sebastian , Lee, Raphael , Job, Emma , Reading, Patrick , Petrie, Stephen , McCaw, James , McVernon, Jodie , Hurt, Aeron , Kelso, Anne , Mosse, Jennifer , Barr, Ian , Laurie, Karen
- Date: 2013
- Type: Text , Journal article
- Relation: PLoS Pathogens Vol. 9, no. 5 (2013), p. 1-18
- Full Text:
- Reviewed:
- Description: Surveillance data indicate that most circulating A(H1N1)pdm09 influenza viruses have remained antigenically similar since they emerged in humans in 2009. However, antigenic drift is likely to occur in the future in response to increasing population immunity induced by infection or vaccination. In this study, sequential passaging of A(H1N1)pdm09 virus by contact transmission through two independent series of suboptimally vaccinated ferrets resulted in selection of variant viruses with an amino acid substitution (N156K, H1 numbering without signal peptide; N159K, H3 numbering without signal peptide; N173K, H1 numbering from first methionine) in a known antigenic site of the viral HA. The N156K HA variant replicated and transmitted efficiently between naïve ferrets and outgrew wildtype virus in vivo in ferrets in the presence and absence of immune pressure. In vitro, in a range of cell culture systems, the N156K variant rapidly adapted, acquiring additional mutations in the viral HA that also potentially affected antigenic properties. The N156K escape mutant was antigenically distinct from wildtype virus as shown by binding of HA-specific antibodies. Glycan binding assays demonstrated the N156K escape mutant had altered receptor binding preferences compared to wildtype virus, which was supported by computational modeling predictions. The N156K substitution, and culture adaptations, have been detected in human A(H1N1)pdm09 viruses with N156K preferentially reported in sequences from original clinical samples rather than cultured isolates. This study demonstrates the ability of the A(H1N1)pdm09 virus to undergo rapid antigenic change to evade a low level vaccine response, while remaining fit in a ferret transmission model of immunization and infection. Furthermore, the potential changes in receptor binding properties that accompany antigenic changes highlight the importance of routine characterization of clinical samples in human A(H1N1)pdm09 influenza surveillance.
- Authors: Guarnaccia, Teagan , Carolan, Louise , Maurer-Stroh, Sebastian , Lee, Raphael , Job, Emma , Reading, Patrick , Petrie, Stephen , McCaw, James , McVernon, Jodie , Hurt, Aeron , Kelso, Anne , Mosse, Jennifer , Barr, Ian , Laurie, Karen
- Date: 2013
- Type: Text , Journal article
- Relation: PLoS Pathogens Vol. 9, no. 5 (2013), p. 1-18
- Full Text:
- Reviewed:
- Description: Surveillance data indicate that most circulating A(H1N1)pdm09 influenza viruses have remained antigenically similar since they emerged in humans in 2009. However, antigenic drift is likely to occur in the future in response to increasing population immunity induced by infection or vaccination. In this study, sequential passaging of A(H1N1)pdm09 virus by contact transmission through two independent series of suboptimally vaccinated ferrets resulted in selection of variant viruses with an amino acid substitution (N156K, H1 numbering without signal peptide; N159K, H3 numbering without signal peptide; N173K, H1 numbering from first methionine) in a known antigenic site of the viral HA. The N156K HA variant replicated and transmitted efficiently between naïve ferrets and outgrew wildtype virus in vivo in ferrets in the presence and absence of immune pressure. In vitro, in a range of cell culture systems, the N156K variant rapidly adapted, acquiring additional mutations in the viral HA that also potentially affected antigenic properties. The N156K escape mutant was antigenically distinct from wildtype virus as shown by binding of HA-specific antibodies. Glycan binding assays demonstrated the N156K escape mutant had altered receptor binding preferences compared to wildtype virus, which was supported by computational modeling predictions. The N156K substitution, and culture adaptations, have been detected in human A(H1N1)pdm09 viruses with N156K preferentially reported in sequences from original clinical samples rather than cultured isolates. This study demonstrates the ability of the A(H1N1)pdm09 virus to undergo rapid antigenic change to evade a low level vaccine response, while remaining fit in a ferret transmission model of immunization and infection. Furthermore, the potential changes in receptor binding properties that accompany antigenic changes highlight the importance of routine characterization of clinical samples in human A(H1N1)pdm09 influenza surveillance.
- Farrukee, Rubaiyea, Leang, Sookkwan, Butler, Jeff, Lee, Raphael, Maurer-Stroh, Sebastian, Tilmanis, Danielle, Sullivan, Sheena, Mosse, Jennifer, Barr, Ian, Hurt, Aeron
- Authors: Farrukee, Rubaiyea , Leang, Sookkwan , Butler, Jeff , Lee, Raphael , Maurer-Stroh, Sebastian , Tilmanis, Danielle , Sullivan, Sheena , Mosse, Jennifer , Barr, Ian , Hurt, Aeron
- Date: 2015
- Type: Text , Journal article
- Relation: Journal of Antimicrobial Chemotherapy Vol. 70, no. 7 (2015), p. 2004-2012
- Full Text: false
- Reviewed:
- Description: Objectives: The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a widely used neuraminidase inhibitor (NAI) antiviral drug, may have reduced effectiveness against influenza B viruses. Therefore, it is important to study the effect of neuraminidase mutations in influenza B viruses that may further reduce NAI susceptibility, and to determine whether these mutations have the same effect in the two lineages of influenza B viruses that are currently circulating (B/Yamagata-like and B/Victoria-like). Methods: We characterized the effect of 16 amino acid substitutions across five framework residues and four monomeric interface residues on the susceptibility to four different NAIs (oseltamivir, zanamivir, peramivir and laninamivir). Results: Framework residue mutations E117A and E117G conferred highly reduced inhibition to three of the four NAIs, but substantially reduced neuraminidase activity, whereas other framework mutations retained a greater level of NA activity. Mutations E105K, P139S and G140R of the monomeric interface were also found to cause highly reduced inhibition, but, interestingly, their effect was substantially greater in a B/Victoria-like neuraminidase than in a B/Yamagata-like neuraminidase, with some susceptibility values being up to 1000-fold different between lineages. Conclusions: The frequency and the effect of key neuraminidase mutations on neuraminidase activity and NAI susceptibility can differ substantially between the two influenza B lineages. Therefore, future surveillance, analysis and interpretation of influenza B virus NAI susceptibility should consider the B lineage of the neuraminidase in the same manner as already occurs for different influenza A neuraminidase subtypes.
- «
- ‹
- 1
- ›
- »